Beyond GLP-1
GLP-1 drugs have transformed the treatment of obesity and type 2 diabetes in recent years, but they do not work equally well for everyone. Some patients lose less weight than expected, others cannot tolerate the side effects, and many reach a plateau after initial success.
Amylin offers drugmakers another biological lever. Like GLP-1, it signals fullness, suppresses appetite and slows the passage of food through the stomach, but it does so through a different pathway. The idea is that targeting several hormonal pathways at once could deliver greater benefits than raising the dose of a single drug.
Lilly's eloralintide results
This week, Lilly released mid-stage trial results for eloralintide, its experimental amylin drug, tested both alone and in combination with tirzepatide, the active ingredient in its Zepbound and Mounjaro injections.
- At 48 weeks, patients with obesity and type 2 diabetes on the highest-dose combination lost an average of 23.3% of their body weight, compared with 14.8% for those on tirzepatide alone, based on an analysis assuming patients stayed on treatment.
- Experts note that people with type 2 diabetes usually lose less weight on such therapies than those without diabetes, making the results especially encouraging.









